Meeting
2023 ASCO Annual Meeting
A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.
Authors
Guangwen Yuan
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Guangwen Yuan , Zhiping Li , Feng Ye , Bingzhong Zhang , Lin Shen , Yan-qiao Zhang , Xianjun Yu , Ying Cheng , Baorui Liu , Jianliu Wang , Xiaojun Chen , Jinghong Zhou , Haiyan Shi , Panfeng Tan , Songhua Fan , Michael Shi , Weiguo Su , Lingying Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Other Gynecologic Cancer
Clinical Trial Registration Number
NCT04169672
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5609)
DOI
10.1200/JCO.2023.41.16_suppl.5609
Abstract #
5609
Poster Bd #
304
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.
First Author: Ting Han
Poster
2023 ASCO Annual Meeting
A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
First Author: Dongmei Ji
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang